AI assistant
PYC THERAPEUTICS LIMITED — Board/Management Information 2014
Jan 23, 2014
65640_rns_2014-01-23_dc1cbc7e-09ad-410e-ac33-8aee304d4cb7.pdf
Board/Management Information
Open in viewerOpens in your device viewer
==> picture [61 x 58] intentionally omitted <==
==> picture [36 x 32] intentionally omitted <==
Market Announcements Platform Australian Securities Exchange
DIRECTOR APPOINTMENT – DR BERNARD HOCKINGS
PERTH, AUSTRALIA: 24 January 2014 – Leading peptide drug discovery company Phylogica Ltd (ASX: PYC, XETRA: PH7) is pleased to announce the appointment of Dr Bernard Hockings as a director.
Dr Hockings is a cardiologist in Perth and became a substantial shareholder in August 2012, subsequently increasing his shareholding to 22.49% through participation in the 2012 converting note and underwriting of the December 2013 rights issue.
The Phylogica board welcomes Dr Hockings and looks forward to his contribution to the Company’s development.
-ends-
Enquiries:
Mr Graeme Boden Dr Richard Hopkins Rudi Michelson Company Secretary CEO Monsoon Communications Tel: +61 (0)8 9286 1219 Tel: +61 (0)405 656 868 Tel + 61 3 9620 3333 [email protected] [email protected] [email protected]
About Phylogica
Phylogica Limited (ASX: PYC) is a biotechnology company based in Perth, Australia with a world-class drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics. The Company was incorporated in 2001 as a spin out from the Telethon Institute for Child Health Research (Perth, Australia) and the Fox Chase Cancer Centre (Philadelphia, USA). The Company’s drug discovery platform is based on its proprietary Phylomer[®] libraries containing over 400 billion unique natural peptides, which have been optimised by evolutionary selection to have stable drug-like structures. Phylogica offers fully integrated drug discovery services to the pharmaceutical industry utilising its Phylomer[®] libraries and proprietary screening technologies. Its current partners include Genentech (a member of the Roche Group), MedImmune (the worldwide biologics arm of AstraZeneca), Pfizer and Janssen (the pharmaceutical arm of Johnson & Johnson).
About Phylomer[®] Peptides
Phylomer peptides are derived from biodiverse natural sequences, which have been selected by evolution to form stable structures, which can bind tightly, and specifically to disease associated target proteins, both inside and outside cells. Suitable targets for blockade by Phylomers include protein interactions that promote multiple diseases, such as infectious diseases, cancer, autoimmunity and heart disease. Phylomer peptides can have drug-like properties, including specificity, potency and thermal stability, and are capable of being produced by synthetic or recombinant manufacturing processes. Phylomer peptides are also readily formulated for administration by a number of means, including parenteral or intranasal delivery approaches.
PO Box 8207, Subiaco East, Western Australia 6008 Tel: +61 8 9384 3284 Fax: +61 8 9284 3801 www.phylogica.com ABN 48 098 391 961